YOU WONT BELIEVE: Novo | Mind Blowing Facts

Employer GLP-1 Coverage Falls to 53% as Workers Losing Wegovy or Zepbound in 2027 Weigh Prices and Appeals

Employer coverage of GLP-1 drugs for weight loss has declined, prompting workers to review plan changes, compare self-pay options, and discuss appeals or treatment transitions with clinicians.

Medical Daily · 14h ago

Women Lost 25% of Body Weight on CagriSema in Trial Analysis, but Most Users Had Digestive Side Effects

Women on CagriSema lost 25% of their body weight in a post hoc trial analysis, while 79.6% of users had digestive side effects. The drug is not approved.

Medical Daily · Oct 21

Ozempic and Zepbound Makers Report Slower Aging Clocks, but Unreviewed Data Do Not Prove Patients Age Slower

Novo Nordisk and Eli Lilly say GLP-1 drugs slowed aging clocks, but the data are early and unreviewed. Here is what patients should know.

Medical Daily · Oct 8

Participants Taking CagriSema Showed Changed Brain Responses to High-Calorie Food Images in Novo Study as FDA Decision Nears

Novo says brain scans showed CagriSema changed food-cue responses and cut cravings. The data are early, and an FDA decision is expected in late 2026.

Medical Daily · Oct 2

Patients Who Switched from Weight-Loss Shots to the Wegovy Pill Lost 4.1% of Body Weight in Three Months

Early real-world data show that 194 people who switched from GLP-1 shots to the Wegovy pill lost 4.1% of body weight in three months. Here's the catch.

Medical Daily · Oct 2

Novo Nordisk Licenses Experimental Once-Weekly Obesity Pill From China's Hengrui in Deal Worth Up to $2.6 Billion

Novo Nordisk will pay $300 million upfront, and up to $2.6 billion in total, for Hengrui's once-weekly GLP-1/GIP pill, which has not been tested in people.

Medical Daily · Oct 1

People Who Took Wegovy Pill Instead Of Injection Still Lost Weight, Data Suggests

The real-world study did not establish causality, but the results could mean the pill might help people maintain the weight-loss results they saw after injections.

International Business Times · Sep 30

Eli Lilly vs. Novo: The Hidden Battle Behind the Weight-Loss Platform Reshaping Industries

GLP-1 is a drug platform, not one product. Lilly leads; Novo slips; Pfizer, Amgen, Roche, and AbbVie chase, with pricing, generic and trial risks.

Barchart · Sep 30

Novo Nordisk Increasingly Calls Wegovy Users Customers, Months After FDA Flagged a 'Live Lighter' Pill Ad Claim

STAT reports Novo now markets Wegovy to customers, months after the FDA called a Wegovy pill ad misleading. What cash-pay buyers should check first.

Medical Daily · Sep 30

Retatrutide Diabetes Results, Mounjaro Heart Data, and Wegovy Pill Switching Study Lead EASD 2026 Meeting Opening in Milan

EASD 2026 opens in Milan with retatrutide, Mounjaro heart, and Wegovy pill data due this week. Here is the schedule and what the numbers show.

Medical Daily · Sep 28